SuperworthVericel EPS VCEL
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.46
- Latest quarter, Q2 FY26
- $0.04
- Fiscal year 2025
- $0.30
- +67% on the year before
Vericel's earnings per share was $0.46 over the twelve months to Jun 30, 2026, up 283% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.04.
Over the five fiscal years to FY2025 it grew 43% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.30 | +67% |
| FY2024 | $0.18 | n/a |
| FY2023 | −$0.08 | n/a |
| FY2022 | −$0.35 | n/a |
| FY2021 | −$0.16 | −420% |
| FY2020 | $0.05 | n/a |
| FY2019 | −$0.24 | n/a |
| FY2018 | −$0.23 | n/a |
| FY2017 | −$0.53 | n/a |
| FY2016 | −$1.18 | n/a |
| FY2015 | −$0.97 | n/a |
| FY2014 | −$3.19 | n/a |
| FY2013 | −$6.69 | n/a |
| FY2012 | −$16.40 | n/a |
| FY2011 | −$10.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.04 | n/a | $0.46 | |
| Q1 FY26 | −$0.12 | n/a | $0.41 | |
| Q4 FY25 | $0.44 | +16% | $0.30 | |
| Q3 FY25 | $0.10 | n/a | $0.24 | |
| Q2 FY25 | −$0.01 | n/a | $0.12 | |
| Q1 FY25 | −$0.23 | n/a | $0.03 | |
| Q4 FY24 | $0.38 | +41% | $0.18 | |
| Q3 FY24 | −$0.02 | n/a | $0.07 | |
| Q2 FY24 | −$0.10 | n/a | $0.01 | |
| Q1 FY24 | −$0.08 | n/a | $0.00 | |
| Q4 FY23 | $0.27 | +108% | −$0.08 | |
| Q3 FY23 | −$0.08 | n/a | −$0.22 |
Against its peers
Companies in Biotechnology nearest Vericel's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| Peer median | $2.17 |
Where Vericel ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vericel
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.